Clinical and preclinical advances in PSMA-Directed Antibody-Drug conjugates (ADCs): Current status and hope for the future-Reference-Cited by-同舟云学术

Clinical and preclinical advances in PSMA-Directed Antibody-Drug conjugates (ADCs): Current status and hope for the future

Published:2024-12 Issue: Volume:153 Page:107803
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Mirzaei Yousef,Hussein Mer Ali,fattah Maran Bahia,Omidvar Leila,Misamogooe Fatemeh,Amirkhani Zahra,Javaheri Haghighi Nafiseh,Bagheri Nader,Keshtkaran Zahra,Rezaei Behzad,Bargrizaneh Farshad,Jahandideh Saeed,Barpour Nesa,Shahsavarani Hosein,Bazyari Ahmadreza,Abdollahpour‐Alitappeh Meghdad

Publisher

Elsevier BV

Reference90 articles.

1. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen;Wang;Mol. Cancer Ther.,2011

2. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer;Milowsky;Urol. Oncol.,2016

3. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen;Ma;Clin. Cancer Res.,2006

4. A PSMA-targeted doxorubicin small-molecule drug conjugate;Yoon;Bioorg. Med. Chem. Lett.,2024

5. S. Cho, F. Zammarchi, D.G. Williams, C.E.G. Havenith, N.R. Monks, P. Tyrer, F. D'Hooge, R. Fleming, K. Vashisht, N. Dimasi, F. Bertelli, S. Corbett, L. Adams, H.W. Reinert, S. Dissanayake, C.E. Britten, W. King, K. Dacosta, R. Tammali, K. Schifferli, P. Strout, M. Korade, 3rd, M.J. Masson Hinrichs, S. Chivers, E. Corey, H. Liu, S. Kim, N.H. Bander, P.W. Howard, J.A. Hartley, S. Coats, D.A. Tice, R. Herbst, P.H. van Berkel, Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer, Mol Cancer Ther 17(10) (2018) 2176-2186.